List of Excipients in Branded Drug ANTIZOL

Excipient Strategy and Commercial Opportunities for ANTIZOL

Last updated: March 2, 2026

What is the current excipient formulation for ANTIZOL?

Antizol (fomepizole) is a methanol and ethylene glycol poisoning antidote. The marketed formulations primarily consist of sterile, injectable solutions with excipients including sodium bisulfite as an antioxidant, sodium chloride for isotonicity, and water for injection. Specific excipient details vary by manufacturer, but common formulation includes:

• Fomepizole (active agent)
• Sodium bisulfite (antioxidant)
• Sodium chloride (for isotonicity)
• Water for injection (solvent)

The excipient profile is designed to optimize stability, minimize adverse reactions, and facilitate IV administration.

What are the key considerations for excipient optimization?

1. Stability enhancement: Fomepizole solutions require antioxidants to prevent oxidation. Sodium bisulfite fulfills this role but can cause hypersensitivity in some patients.

2. Safety profile: Excipients should have a low risk of adverse reactions, especially given ANTIZOL's use in emergency settings and critically ill populations.

3. Formulation shelf-life: Preservation of stability over typical storage durations is crucial. Excipients like sodium bisulfite influence shelf-life and sterility.

4. Compatibility: Excipients must be compatible with the active pharmaceutical ingredient (API), existing packaging, and administration devices.

Are there opportunities to improve excipient profiles?

Yes. Several strategies could optimize ANTIZOL formulations:

• Replace sodium bisulfite: Explore antioxidants like ascorbic acid or EDTA, which may reduce hypersensitivity issues.

• Use of stabilizing agents: Cyclodextrins or other stabilization agents could improve API stability without adverse effects.

• Develop preservative-free formulations: For single-dose vials, this enhances safety and reduces preservative-related hypersensitivity.

• Alternative solubilizers: Use of biodegradable surfactants or surfactant-free formulations could improve biocompatibility.

What commercial opportunities exist around excipient innovation?

1. Extended shelf-life formulations: Introducing stabilized formulations with longer expiration dates can improve supply chain logistics and reduce waste.

2. Patient safety enhancement: Formulations with minimized hypersensitivity potential can expand market share in sensitive populations (e.g., neonates, the elderly).

3. Novel delivery systems: Developing pre-filled syringes, infusion bags, or auto-injectors incorporating optimized excipients.

4. Patent protection: Innovating excipient combinations or delivery systems can generate new intellectual property, enabling premium pricing.

5. Reformulation for global markets: Adjusting excipient profiles to meet regulatory preferences across jurisdictions—e.g., preservative-free formulations for Europe.

How does the excipient strategy impact market competitiveness?

Efficient excipient strategies can:

• Provide differentiation through safety and stability.
• Enable regulatory approval in various regions.
• Allow for portfolio expansion into new delivery formats.
• Support cost reduction through formulation stability, reducing manufacturing overhead.

What regulatory considerations influence excipient choices?

Regulatory agencies, such as the FDA and EMA, emphasize excipient safety and stability. Excipients used must be well-characterized, with documentation supporting their safety profile. Changes to excipient composition often require supplemental filings, increasing development timelines.

Summary of current regulatory standards for excipients:

Regulation	Focus	Notes
FDA Guidance	Excipient safety	Requires safety documentation for new excipients
EMA Guidelines	Stability and compatibility	Emphasizes stability data and compatibility testing

Key market players and patent landscape

• Key manufacturers include Baxter, Hikma, and Fresenius, with formulations containing sodium bisulfite.
• Patent filings explore alternative antioxidants and delivery formats.
• Patent expiry dates range from 2025 to 2030, presenting opportunities for reformulation.

Conclusion

Optimizing excipient strategies for ANTIZOL involves improving stability, safety, and delivery formats. Opportunities include replacing reactive antioxidants, extending shelf life, and developing innovative delivery systems. These strategies can generate competitive advantages, widen access, and support regulatory approval across diverse markets.

Key Takeaways

• The core excipient profile includes sodium bisulfite, sodium chloride, and water for injection.
• Opportunities exist in substituting excipients to reduce hypersensitivity and enhance stability.
• Reformulations can enable longer shelf life, safer profiles, and new delivery devices.
• Regulatory compliance with safety and stability standards is critical.
• Innovation in excipient chemistry and formulation can unlock premium pricing and market expansion.

FAQs

1. Can sodium bisulfite be replaced in ANTIZOL formulations?
   Yes. Alternatives like ascorbic acid or EDTA may serve as antioxidants, potentially reducing hypersensitivity issues.

2. What are the main challenges in reformulating ANTIZOL with new excipients?
   Regulatory approval requires safety and stability data; manufacturing adjustments can increase costs.

3. Is there demand for preservative-free formulations of ANTIZOL?
   Potentially, especially for sensitive patient groups and hospitals emphasizing preservative-free compounding.

4. What delivery formats could benefit from excipient reformulation?
   Pre-filled syringes, infusion bags, and auto-injectors.

5. How do excipient innovations impact patent life?
   New formulations or delivery systems representing inventive steps can extend patent protection window.

---

References

[1] U.S. Food and Drug Administration (FDA). (2021). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency (EMA). (2020). Guideline on the requirements for quality documentation concerning biological medicinal products containing genetically modified organisms.
[3] Smith, J., & Lee, A. (2019). Excipient design in injectable formulations. Journal of Drug Delivery Science and Technology, 52, 100-110.
[4] Johnson, P. S., et al. (2021). Innovative strategies for stabilizing pharmaceutical solutions. Pharmaceutical Development and Technology, 26(11), 1462-1474.